1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > United States Market for Ankylosing Spondylitis Pharmacotherapy

This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.

Executive Summary
•The market for ankylosing spondylitis (AS) add-on pharmacotherapeutics currently comprises a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for TNF inhibitor refractory patients with moderate to severe disease represents a significant unmet need.
•Revenue generated from sales of TNF inhibitors for AS in the United States was approximately $x million in 2011 and was dominated by Abbott. Revenue for the AS therapeutic area is expected to increase to approximately $x million in 2017.
•Novel therapies aimed at alternative targets such as interleukin-17 (IL-17), interleukin 12/23 (IL-12/23), phosphodiesterase type 4 (PDE4), and janus kinase (JAK) are in active development, with an anti-IL-17 closest to approval for AS.
•Development of therapies for this complex disease is hindered by several factors, including incompletely understood pathogenesis of AS and a low level of disease awareness.
•Estimates of the prevalence of AS vary widely, but it occurs in approximately xx percent of the adult population. It usually presents in young adults, with a higher prevalence in males versus females.
•While many patients will respond well to non-steroidal anti-inflammatory drugs (NSAIDs), approximately .... percent (just under 200,000 in the United States in 2011) do not and are candidates for add-on therapy such as biologics.
•Diagnosis and initiation of appropriate treatment is often delayed by up to ten years due to unawareness of the disease.

Table Of Contents

United States Market for Ankylosing Spondylitis Pharmacotherapy
TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Total Ankylosing Spondylitis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 22
Forecasts and Trends 32
Demand Analysis 43
Market Share and Competitive Analysis 46
TNF Inhibitor Segment Breakdown 55
Non-TNF Biologics Segment Breakdown 66
The Last Word (Conclusions and Implications) 74
Appendix 79

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • April 2015
  • by Global Data

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023 Summary Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into ...

OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019

OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019

  • $ 7 995
  • Industry report
  • April 2015
  • by Global Data

OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 Summary Duchenne muscular dystrophy (DMD) is a rare genetic disorder affecting approximately 1 in 3,500 newborn ...

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Therapy Markets In China

July 2015 $ 4 000

Download Unlimited Documents from Trusted Public Sources

Therapy Industry in the US

  • July 2015
    11 pages
  • Therapy  

    Cancer Therapy  

    Hepatitis B  

  • United States  

View report >

Oncology Industry in the US - Forecast

  • June 2015
    6 pages
  • Oncology  

    Cancer Therapy  

    Cancer  

  • United States  

View report >

Oncology Industry in Australia - Forecast

  • June 2015
    4 pages
  • Oncology  

    Chemotherapy  

    Cancer  

  • Australia  

View report >

Related Market Segments :

Therapy

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.